Julie Schulz, MD, MPH, Physician Executive, Product leader, and VP of Product, and Michael Dovidio, PharmD, Product Manager at Avalon Healthcare Solutions, discuss why leveraging cardiometabolic lab values instead of BMI to determine coverage for GLP-1 drugs would improve prescription availability for diabetic and obese patients.
","author_name":"Urban Health Weekly"}